精神分裂症疾病负担及药物治疗现状困境  

Disease Burden and the Dilemmas of Antipsychotic Agents in Schizophrenia:A Review

作　　者：黄兢 唐慧[1] 伍海姗[1] 向慧[1] 刘晶 李乐华[1] 吴仁容[1] 陈晋东[1] HUANG Jing;TANG Hui;WU Hai-Shan;XIANG Hui;LIU Jing;LI Le-Hua;WU Ren-Rong;CHEN Jin-Dong(Department of Psychiatry,Second Xiangya Hospital,Central South University,Changsha 410001,China;Sumitomo Pharma(Suzhou)Co,Ltd,Shanghai 200001,China)

机构地区：[1]中南大学湘雅二医院精神卫生研究所,长沙410001 [2]住友制药(苏州)有限公司,上海200001

出　　处：《中国药物经济学》2022年第11期16-21,26,共7页China Journal of Pharmaceutical Economics

摘　　要：精神分裂症疾病负担沉重,已在全球范围内造成公共卫生影响。其主要治疗方式为药物治疗,然而目前的抗精神病药仍具有一定的局限性。例如对阴性症状、残留阳性症状和认知功能等方面的治疗并不理想,以及药物不良反应和依从性差等问题,均是临床治疗亟需突破的困境。因此,有必要对精神分裂症在国内外的疾病负担、药物治疗现状和困难进行综述,以便帮助临床医师深入理解该病,并为医疗卫生决策者提供参考依据。Schizophrenia is a chronic debilitating mental illness,thus imposing a heavy burden and major public health implications all over the world.Although therapy of schizophrenia mainly relies on medication,the current antipsychotic agents are characterized by some limitations.For example,they ameliorate mainly positive symptoms,while negative and cognitive symptoms remain untreated.Some of these agents involve severe neurological and metabolic side effects and may lead to poor adherence.These problems often leading to treatment dilemmas in clinical practice.Therefore,it is necessary to summarize the disease burden,the current treatment patterns and difficulties of antipsychotic therapy in schizophrenia at home and abroad,so as to help clinicians deeply understand the disease and provide reference to medical and health decision-makers.

关 键 词：精神分裂症 疾病负担 抗精神病药物 困境 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R971[医药卫生—临床医学]